Zoryl M2 Forte Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The prolonged-release formulation ensures a steady plasma concentration, reducing gastrointestinal side effects commonly associated with immediate-release metformin and improving patient compliance. Zoryl M2 Forte is prescribed as an adjunct to diet and exercise to achieve optimal blood glucose levels in patients inadequately controlled on monotherapy or lifestyle modifications alone. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Caution is advised in patients with cardiovascular disease or risk factors for lactic acidosis. Regular monitoring of blood glucose, renal function, and hepatic parameters is essential during therapy. Common adverse effects include gastrointestinal disturbances, hypoglycemia, and rarely, lactic acidosis. Dose adjustments should be individualized based on therapeutic response and tolerability. Zoryl M2 Forte Tablet PR should be used under strict medical supervision to optimize diabetes management and minimize complications.